Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Toray Makes $5 Million Strategic Investment in Spectral Diagnostics

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
Private placement expected to close at the beginning of April, 2013.

Spectral Diagnostics Inc. has announced that it has entered into a private placement agreement with Toray Industries, Inc. ("Toray"), pursuant to which Toray will invest $5 million in Spectral.

Under the terms of the private placement (the "Private Placement"), the Company will issue 16,666,667 common shares in the capital of the Company ("Common Shares") to Toray at a price of $0.30 per Common Share, for gross proceeds of $5 million.

The net proceeds of the Private Placement will be used to continue to support the Company's EUPHRATES clinical trial and for general corporate purposes.

Following the closing of the Private Placement, Toray's investment will represent approximately 12.8% of the issued and outstanding Common Shares, calculated on a non-diluted basis.

Under the terms of the Private Placement, Toray will be entitled to nominate one director to the Spectral board for as long as it holds 10% or more of the issued and outstanding Common Shares (calculated on a non-diluted basis).

"This strategic investment not only provides additional funds for our clinical trial, but also strengthens the existing collaborative relationship we have with Toray," said Anthony Businskas, Executive Vice President and CFO of Spectral.

Businskas continued, "We will work with Toray to complete clinical research for U.S. FDA market approval of Toraymyxin, and we will seek to further expand acceptance of the EAATM/ Toraymyxin theranostic in jurisdictions outside of Japan."

Closing of the Private Placement is subject to the approval of the Toronto Stock Exchange and other customary closing conditions. The Private Placement is currently expected to close at the beginning of April, 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
Additional exclusion criterion added to the clinical protocol.
Thursday, June 05, 2014
Spectral Updates Status of EUPHRATES Trial
Trial to continue with a total of 650 patients.
Tuesday, April 15, 2014
Spectral Announces Fourth Quarter and Fiscal 2013 Results
Company announces fourth quarter highlights and financial review.
Tuesday, April 01, 2014
Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
Company has scheduled the next DSMB meeting for early April 2014.
Thursday, March 13, 2014
Spectral Announces Status of Second Interim Analysis
DSMB evaluates the safety, efficacy and futility of Company’s EUPHRATES trial.
Friday, January 31, 2014
Spectral Announces Third Quarter 2013 Results
Company to disclose information from the second interim analysis in early 2014.
Monday, November 18, 2013
Spectral Announces Second Quarter 2013 Results
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Wednesday, August 14, 2013
Spectral Provides Update on its EUPHRATES Trial
Trial is on track and continues to enroll patients at an accelerated rate.
Monday, August 05, 2013
Spectral Appoints Vice President of Sales and Marketing
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Tuesday, July 09, 2013
Spectral Announces First Quarter 2013 Results
Company's Phase III EUPHRATES trial enrolled by the end of 2014.
Thursday, May 16, 2013
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board
Enrolment in the EUPHRATES trial is continuing with no safety issues.
Wednesday, February 06, 2013
Spectral Announces Third Quarter 2012 Results
U.S. FDA approved an amended protocol for Spectral's Phase III EUPHRATES trial.
Friday, November 16, 2012
Spectral Announces Second Quarter 2012 Results
Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Friday, August 17, 2012
Spectral Diagnostics Provides Update on Euphrates Trial
FDA allows Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Monday, June 25, 2012
Spectral Diagnostics to Present at BioFinance 2012
Conference to be held at the St. Andrew's Club & Conference Centre in Toronto, Ontario.
Monday, May 21, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Fat Cells That Amplify Nerve Signals in Response to Cold Also Affect Blood Sugar Metabolism
Researchers at UTSW have found that the protein connexin 43 forms cell-to-cell communication channels on the surface of emerging beige fat cells that amplify the signals from those few nerve fibers.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!